Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Read more about Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Read more about Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Read more about Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Read more about Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Read more about Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. Read more about Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Read more about Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Read more about Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Read more about Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.
The burden of malignant melanoma--lessons to be learned from Austria. Read more about The burden of malignant melanoma--lessons to be learned from Austria.
